← Back
NeuroTrials.ai
Neurology Clinical Trial Database

VENOST

A Multicenter Study of 1144 Patients with Cerebral Venous Thrombosis: The VENOST Study

Year of Publication: 2017

Authors: Taskin Duman, MD, Derya Uluduz, ..., and VENOST Study Group

Journal: Journal of Stroke and Cerebrovascular Diseases

Citation: Journal of Stroke and Cerebrovascular Diseases, Vol.(), No.(), 2017: pp-. 10.1016/j.jstrokecerebrovasdis.2017.04.070

Link: https://www.researchgate.net/publication...he_VENOST_Study

PDF: https://www.researchgate.net/profile/Meh...saWNhdGlvbiJ9fQ


Clinical Question

To characterize the clinical characteristics, risk factors, and outcomes of Caucasian patients with cerebral venous thrombosis (CVT) in a large, multicenter study, comparing these features across age and sex distributions.

Bottom Line

The VENOST study, a large multicenter observational study of Caucasian CVT patients, found clinical and radiological features consistent with previous studies, but identified different predisposing factors, notably a higher incidence of puerperium and lower oral contraceptive use. Malignancy, older age, and hemorrhagic infarcts were associated with worse outcomes, while epileptic seizures had no negative impact.

Major Points

  • The study included 1144 patients with confirmed CVT from 35 national stroke centers in Turkey, with data collected retrospectively (2000-2013) and prospectively (after 2013).
  • 67.9% of patients were women, but male patients were more prevalent in the older age group (>50 years) (27.8% vs 16.6% in women; P<.001).
  • The most frequent symptoms were headache (87.2%), nausea and vomiting (27.7%), visual field defects (26.5%), and epileptic seizures (23.7%). Headache was the sole symptom in 25.1% of patients.
  • Gynecological factors (puerperium 18.3%, oral contraceptive use 13.9%, pregnancy 9.5%) comprised the largest etiological group in women. Oral contraceptive use was not a prevalent risk factor in this cohort.
  • Prothrombotic conditions (26.4%), mainly MTHFR mutation (6.3%) and Factor V Leiden mutation (5.1%), were the most common etiologies in both genders.
  • Infection-associated etiology was found in 8.1% of patients and malignancy-related in 5.2%; both were significantly higher in men and older age groups (P<.001).
  • Parenchymal involvement (constitutively hemorrhagic infarcts), malignancy, and older age were associated with higher modified Rankin Scale (mRS) scores (worse outcome).
  • Epileptic seizures had no effect on prognosis. Patients with focal neurological deficit and altered consciousness had unfavorable prognosis.
  • Most patients were anticoagulated (83.9%) in the early period with intravenous heparin (69.6%) or subcutaneous low-molecular weight heparin (14.3%).
  • At 1-month follow-up, 78.4% of patients had mRS 0-1, 11.7% had mRS 2, and 10.0% had mRS 3-5. No patients had mRS 6 due to CVT.
  • Outcome was favorable in patients with no parenchymal lesions and worst in patients with hemorrhagic infarcts. Outcome was favorable in infectious-related CVT but unfavorable in malignancy.

Design

Study Type: National, multicenter, retrospective and prospective, hospital-based observational study

Randomization:

Enrollment Period: Data collected between 2000 and 2015. Retrospective enrollment for 2000-2013, prospective enrollment after 2013.

Follow-up Duration: Up to 12 months (follow-up visits recorded after 1, 3, 6, and 12 months if available).

Centers: 35

Countries: Turkey

Sample Size: 1144

Analysis: Continuous data summarized as mean±standard deviation or median with interquartile range; categorical data as frequency and percent. Independent sample t-test for continuous variables, Pearson chi-square or likelihood ratio test for categorical data. Multivariate logistic regression for odds ratios (OR) for prognostic factors. SPSS v.22 statistical package used.


Inclusion Criteria

  • Patients aged more than 18 years.
  • Radiologically confirmed cerebral venous and sinus thrombosis (CVST) based on clinical presentation and thrombosis on cranial CT, MRI, MRV, and DSA.
  • Caucasian patients.

Exclusion Criteria

  • 49 patients were excluded as their data were inconclusive.

Baseline Characteristics

CharacteristicControlActive
Female, n (%)787 (67.9)
Male, n (%)357 (32.1)
Age group 18-36, n (%)533 (46.6)
Age group 37-50, n (%)380 (33.2)
Age group 51+, n (%)231 (20.2)
Mode of onset - Acute, n (%)530 (47.1)
Mode of onset - Subacute, n (%)383 (34.0)
Mode of onset - Chronic, n (%)213 (18.9)
Isolated headache, n (%)287 (25.1)
Headache, n (%)997 (87.2)
Nausea and vomiting, n (%)317 (27.7)
Epileptic seizures, n (%)271 (23.7)
Visual field defect, n (%)303 (26.5)
Focal neurological deficit, n (%)208 (18.2)
Altered consciousness, n (%)204 (17.8)
Cranial nerve palsies, n (%)128 (11.2)
Radiological workup - Cranial MRI, n (%)60 (5.3)
Radiological workup - Cranial MRV, n (%)41 (3.6)
Radiological workup - Cranial MRI + MRV, n (%)1015 (89.1)
Radiological workup - Cerebral angiography, n (%)23 (2.0)
Number of sinuses involved - 1 sinus, n (%)551 (48.2)
Number of sinuses involved - 2 sinuses, n (%)387 (33.8)
Number of sinuses involved - More than 2 sinuses, n (%)206 (18.0)
Involved sinuses - Isolated transverse sinuses, n (%)292 (25.5)
Involved sinuses - Isolated sagittal sinuses, n (%)168 (14.7)
Involved sinuses - Isolated sigmoid sinuses, n (%)37 (3.2)
Involved sinuses - Isolated cortical veins, n (%)24 (2.1)
Involved sinuses - Isolated jugular sinuses, n (%)16 (1.4)
Involved sinuses - Isolated cavernous sinuses, n (%)9 (0.8)
Involved sinuses - Transverse sinuses, n (%)840 (73.4)
Involved sinuses - Sigmoid sinuses, n (%)455 (39.8)
Involved sinuses - Sagittal sinuses, n (%)445 (38.9)
Involved sinuses - Internal jugular vein, n (%)178 (15.6)
Involved sinuses - Cortical veins, n (%)42 (3.7)
Involved sinuses - Cavernous sinuses, n (%)19 (1.7)
Parenchymal involvement - No lesion, n (%)685 (59.9)
Parenchymal involvement - Infarction, n (%)218 (19.1)
Parenchymal involvement - Hemorrhagic infarction, n (%)198 (17.3)
Parenchymal involvement - Intracerebral hemorrhage, n (%)43 (3.8)
Gynecological causes - Oral contraceptive use, n (%)108 (13.9)
Gynecological causes - Pregnancy, n (%)74 (9.5)
Gynecological causes - Puerperium, n (%)142 (18.3)
Infections - Paracranial (focal), n (%)70 (6.1)
Infections - Systemic, n (%)23 (2.0)
History of VTE - Cerebral, n (%)26 (1.9)
History of VTE - Deep venous thrombosis, n (%)34 (3.0)
History of VTE - Other, n (%)4 (0.8)
Malignancy, n (%)59 (5.2)
Family history of VTE, n (%)11 (1.0)
MTHFR mutation heterozygote, n (%)37 (5.1)
MTHFR mutation homozygote, n (%)46 (6.3)
Hyperhomocysteinemia, n (%)45 (4.8)
Prothrombin mutation, n (%)19 (2.6)
Protein C/S deficiency, n (%)47 (5.0)
Factor V Leiden mutation, n (%)37 (5.1)
Thrombocytosis, n (%)10 (1.1)
Polisitemia vera, n (%)7 (0.7)
Anticardiolipin Ab, n (%)6 (0.6)
PAI mutation, n (%)10 (1.4)
Antithrombin III deficiency, n (%)5 (0.5)
Hyperfibrinogenemia, n (%)3 (0.3)
Antiphospholipid Ab, n (%)11 (1.3)
Activated protein C resistance, n (%)14 (1.5)
High ANA titers, n (%)17 (1.5)
Behçet's disease, n (%)108 (9.4)
SLE, n (%)15 (1.4)
Idiopathic, n (%)281 (24.6)

Arms

FieldObservational CVT cohort
InterventionObservational registry: imaging-confirmed cerebral venous thrombosis patients across 35 Turkish centers (2000–2015). Anticoagulation and other treatments per physician discretion.
DurationUp to 3 months follow-up (and beyond in some patients)

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Functional outcome at 3 months (mRS 0–1) in Caucasian patients with cerebral venous thrombosis, with description of clinical, radiological, and etiological features.Primary
mRS score 0-1 at 1st month visitSecondary787 (78.4%)
mRS score 2 at 1st month visitSecondary117 (11.7%)
mRS score 3-5 at 1st month visitSecondary100 (10.0%)
mRS score 0-1 at 3rd month evaluationSecondary764 (90.6%)0.128
mRS score 2 at 3rd month evaluationSecondary45 (5.3%)0.263
mRS score >3 at 3rd month evaluationSecondary33 (3.9%)<.001
mRS score 0-1 at 6th month follow-upSecondary712 (91.5%)0.011
mRS score 2 at 6th month follow-upSecondary37 (4.8%)0.938
mRS score >3 at 6th month follow-upSecondary29 (3.7%)<.001
mRS score 0-1 at 12th month outcomeSecondary643 (93.1%)0.057
mRS score 2 at 12th month outcomeSecondary22 (3.2%)0.518
mRS score >3 at 12th month outcomeSecondary26 (3.8%)<.001
Outcome favorable in patients with no parenchymal lesions (mRS 0-1)Secondary62.2% of patients with no parenchymal lesions
Outcome unfavorable in patients with focal neurological deficit (mRS >=3)Secondary3.264
Outcome unfavorable in patients with altered consciousness (mRS >=3)Secondary5.856
Outcome favorable in patients without headache (mRS 0-1)Secondary13.2% of patients without headache0.014 (for comparison with headache patients)
Outcome favorable for transverse sinus involvement (mRS 0-2)Secondary73.4% of patients had transverse sinus involvement0.026
Outcome unfavorable for SSS involvement (mRS >=3)Secondary4.2280.001
Outcome favorable for infectious-related CVST (mRS 0-2)Secondary8.1% of patients had infection-associated CVST
Outcome unfavorable for malignancy-related CVST (mRS >=3)Secondary3.3070.003
mRS 0-1 at 1 month (favorable)Adverse787/1004 (78.4%)
mRS 2 at 1 month (minimal disability)Adverse117/1004 (11.7%)
mRS 3-5 at 1 month (dependent)Adverse100/1004 (10.0%)
mRS 6 (death due to CVST) at 1 monthAdverse0 (0%)
Observational study - no AE tableAdverseMulticenter observational cohort - no systematic AE collection

Criticisms

  • The study has an observational nature, lacking uniform evaluation for etiology and treatment options, which may introduce bias.
  • There were high dropout rates from long-term follow-up (e.g., 60.4% at 1 year).
  • The study does not represent the entire CVST patient population, nor is it a random sample, which limits generalizability.
  • Specific details on acute and maintenance treatment duration and dosages, beyond initial anticoagulation, are not uniformly provided for all patients.
  • Information on acquired or congenital thrombophilic abnormalities was collected only if available, not uniformly.
  • The study identified Behçet's disease as an underlying etiology more frequently than Western countries, but the impact of this specific etiology on overall outcomes is not fully explored.
  • The authors mention that the proportion of women was higher in the older age group and acute onset was more common in younger ages, and chronic onset in older age, which could confound some age-related findings.

Subgroup Analysis

Patients were compared by sex and age groups (less than 37 years of age, 37-50 years, and more than 50 years) for clinical symptoms, etiological factors, vascular involvement, and frequency of parenchymal involvement. Prognostic factors (aged >50 years, parenchymal involvement, malignancy, SSS involvement, focal neurological deficit, altered consciousness) were evaluated for association with higher mRS scores (mRS ≥3) using multivariate logistic regression.

Based on: VENOST (Journal of Stroke and Cerebrovascular Diseases, 2017)

Authors: Taskin Duman, MD, Derya Uluduz, ..., and VENOST Study Group

Citation: Journal of Stroke and Cerebrovascular Diseases, Vol.(), No.(), 2017: pp-. 10.1016/j.jstrokecerebrovasdis.2017.04.070

Content summarized and formatted by NeuroTrials.ai.